Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * TABUTEAU HERRIOT 2. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2025 (Street) NEW YORK, NY 10007 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/12/2025 M(1)(2) 27,907 A $8.02 35,136 D Common Stock 09/12/2025 S(2)(3) 27,907 D $118.96(4) 7,229 D Common Stock 09/15/2025 M(1)(2) 15,254 A $8.02 22,483 D Common Stock 09/15/2025 S(2)(3) 15,254 D $117.37(5) 7,229 D Common Stock 09/16/2025 M(1)(2) 19,719 A $8.02 26,948 D Common Stock 09/16/2025 S(2)(3) 19,719 D $114.19(6) 7,229 D Common Stock 7,344,500 I See Footnote(7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$118.96

09/12/2025

M(1)(2)

27,907

05/27/2017

05/27/2026

Common Stock

27,907

$ 0

496,093

D

Stock Option (Right to Buy)

$117.37

09/15/2025

M(1)(2)

15,254

05/27/2017

05/27/2026

Common Stock

15,254

$ 0

480,839

D

Stock Option (Right to Buy)

$114.19

09/16/2025

M(1)(2)

19,719

05/27/2017

05/27/2026

Common Stock

19,719

$ 0

461,120

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
TABUTEAU HERRIOT C/O AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK, NY 10007	X	X	Chief Executive Officer

Signatures

/s/ Nick Pizzie, Attorney-in-Fact		09/16/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year.
(2)	Such transaction was pursuant to a pre-approved 10b5-1 plan.
(3)	Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
(4)	Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $117.81 and $122.54.
(5)	Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $116.70 and $118.44.
(6)	Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $113.01 and $116.10.
(7)	Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.